ABSTRACT
ETHNOPHARMACOLOGICAL RELEVANCE: Murraya koenigii commonly known as curry leaf, is traditionally used in India to manage various ailments including diabetes mellitus. Curry leaves are well documented in Indian Ayurvedic system of medicine for beneficial effects in skin eruptions, dysentery, emesis, poisonous bites and bruises. The anti-hyperglycemic and anti-hyperlipidemic effects of curry leaf extracts have been demonstrated through several in vitro and in vivo experiments previously. AIM OF THE STUDY: To prepare an alkaloid enriched fraction (AEF) from M. koenigii and its evaluation on i) in vitro adipogenesis process and ii) in vivo high fat diet-induced obesity in C57BL/6J mice. MATERIALS AND METHODS: MKME and AEF were prepared from M. koenigii leaves. The four carbazole alkaloids (bioactive markers) isolated from AEF were quantitatively determined in the leaves by RP-HPLC method. MKME and AEF were studied for anti-obesogenic activity in adipocytes in vitro and in HFD-induced C57BL/6J obese mice in vivo. At the termination of the in vivo study, lipid profile, hepatic and renal injury and glucose levels were analyzed in the blood samples. Animal tissues were examined histopathologically to determine any signs of damage. Repeated dose oral toxicity study for 28 days on Sprague-Dawley rats was also performed to determine the safety profile of AEF. RESULTS: Both MKME and AEF displayed anti-obesogenic activity at 25 µg/ml concentration in vitro and showed 54.06 ± 3.86% and 37.46 ± 3.17% lipid accumulation, respectively compared to control. Further, supplementation of AEF and MKME in HFD-fed C57BL/6J mice helped in controlling weight gain, improved dyslipidemia and glucose intolerance significantly. AEF showed better anti-obesity activity than MKME both in vitro and in vivo study. Repeated administration of AEF up to 1 g/kg dose for 28 days showed no pathological tissue damage. Both MKME and AEF were standardized using a simple and validated RP-HPLC method. CONCLUSION: Present study was aimed at preparation of a novel alkaloid-enriched fraction from methanolic extract of M. koenigii leaf and its evaluation for anti-diabesity effect. Our results demonstrated AEF to be a promising plant-based therapy for ameliorating obesity and related metabolic complications in HFD-fed C57BL/6J mice.
Subject(s)
3T3-L1 Cells , Alkaloids , Diet, High-Fat , Mice, Inbred C57BL , Murraya , Obesity , Plant Extracts , Plant Leaves , Animals , Murraya/chemistry , Alkaloids/pharmacology , Plant Leaves/chemistry , Obesity/drug therapy , Diet, High-Fat/adverse effects , Plant Extracts/pharmacology , Mice , Male , Anti-Obesity Agents/pharmacology , Anti-Obesity Agents/isolation & purification , Adipogenesis/drug effects , Adipocytes/drug effectsABSTRACT
Leishmaniasis is a zoonotic disease transmitted by an obligate intra-macrophage protozoan of the genus Leishmania through the infective bite of a vector sandfly. This study investigated the therapeutic efficacy of farnesol, a sesquiterpene compound, for the treatment of cutaneous leishmaniasis (CL) using in vivo BALB/c mouse model. In this study, farnesol's efficacy was compared with the standard drug, paromomycin. It was observed that farnesol significantly reduced lesion sizes and footpad thickness compared to the control group (paromomycin). Lymph node size was also significantly reduced in farnesol-treated mice, indicating its ability to control infection spread. Combination therapy with farnesol and Paromomycin did not demonstrate synergistic effects. These results highlight the potential of farnesol as an alternative therapeutic agent for CL. Further investigations are required to elucidate its mechanism of action and assess potential off-target effects. Optimization of oral delivery methods should be explored to enhance bioavailability. Overall, our findings support farnesol's efficacy in CL treatment, offering promising prospects for improved disease management.
Subject(s)
Leishmania , Leishmaniasis, Cutaneous , Animals , Mice , Farnesol/pharmacology , Farnesol/therapeutic use , Paromomycin , Leishmaniasis, Cutaneous/drug therapy , Administration, Cutaneous , Mice, Inbred BALB CABSTRACT
OBJECTIVE: The aim of the present investigation was to design and formulate appropriate form of glabridin, using microsponge drug delivery system. METHOD: Microsponges were prepared by emulsion solvent evaporation method and characterized by drug loading, infrared spectroscopy and scanning electron microscopy. In vitro diffusion studies of gel formulation were performed using ethanol: phosphate buffer (1:1) mixture as receptor medium. Animal studies were carried out using brownish guinea pigs with UV-induced pigmentation model. RESULTS: Prepared microsponges were predominantly yellowish, free-flowing and spherical in shape. The infrared spectra revealed the absence of drug polymer interaction. Scanning electron microscopy (SEM) and porosity studies confirmed spherical and porous nature. In vitro release studies data depicted highest correlation with Higuchi treatment. Animal studies also supported the better depigmenting activity as compared to plain gel. CONCLUSION: Glabridin microsponge-loaded gel could be efficacious in treating various hyperpigmentation disorders.
Subject(s)
Drug Delivery Systems , Hyperpigmentation/drug therapy , Isoflavones , Phenols , Animals , Disease Models, Animal , Drug Evaluation, Preclinical , Emulsions , Guinea Pigs , Hyperpigmentation/pathology , Isoflavones/chemistry , Isoflavones/pharmacokinetics , Isoflavones/pharmacology , Phenols/chemistry , Phenols/pharmacokinetics , Phenols/pharmacology , Ultraviolet Rays/adverse effectsABSTRACT
Unilateral cerebellar hypoplasia is a relatively rare malformation. We report the case of a 7-year-old boy who presented with a history of a fall, which was followed by cerebellar signs. Imaging findings suggested a diagnosis of unilateral cerebellar hypoplasia. The child recovered with conservative management, probably because the cerebellar signs were due to the trauma and not the hypoplasia itself.
